The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

1. Issuer's Identity				
CIK (Filer ID Number)	Previous Names	None	Entity Type	
0001716947	Leisure Acqui	sition Corp.	X Corporation	
Name of Issuer	1	1	Limited Partnership	
Ensysce Biosciences, Inc.			<u> </u>	
Jurisdiction of Incorporation/Org	ganization		Limited Liability Company	
DELAWARE			General Partnership	
Year of Incorporation/Organiza	tion		Business Trust	
X Over Five Years Ago			Other (Specify)	
Within Last Five Years (Spe	cify Year)			
Yet to Be Formed				
2. Principal Place of Business	and Contact Information			
Name of Issuer				
Ensysce Biosciences, Inc.				
Street Address 1		Street Address 2		
7946 IVANHOE AVE,		SUITE 201		
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer	
LA JOLLA	CALIFORNIA	92037	(858) 263-4196	
3. Related Persons				
Last Name	First Name		Middle Name	
Kirkpatrick	D		Lynn	
Street Address 1	Street Address 2			
7946 Ivanhoe Ave, Suite 201				
City	State/Province/Con	untry	ZIP/PostalCode	
La Jolla Relationship: X Executive Office	CALIFORNIA		92037	
Clarification of Response (if Nec				
Last Name	First Name		Middle Name	
Gower Street Address 1	Bob Street Address 2			
7946 Ivanhoe Ave, Suite 201	Stieet Address 2			
City	State/Province/Co	ıntrv	ZIP/PostalCode	
La Jolla	State/Province/Country CALIFORNIA		92037	
	er X Director Promoter			
Clarification of Response (if Neo	cessary):			
Last Name	First Name		Middle Name	
Chang	William			
Street Address 1	Street Address 2			
7946 Ivanhoe Ave, Suite 201				
City	State/Province/Co	untry	ZIP/PostalCode	
La Jolla	CALIFORNIA		92037	
Relationship: Executive Office	er X Director Promoter			
Clarification of Response (if Neo	cessary):			

Last Name	First Name	Middle Name
Benton	Andrew	
Street Address 1	Street Address 2	
7946 Ivanhoe Ave, Suite 201		
City	State/Province/Country	ZIP/PostalCode
La Jolla	CALIFORNIA	92037
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):	_	
Last Name	First Name	Middle Name
Martin	Steve	Widdle Name
Street Address 1	Street Address 2	
7946 Ivanhoe Ave, Suite 201	Street / tddress 2	
City	State/Province/Country	ZIP/PostalCode
La Jolla	CALIFORNIA	92037
Relationship: Executive Officer X Director	_	72037
	Fromotei	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Levin	Adam	
Street Address 1	Street Address 2	
7946 Ivanhoe Ave, Suite 201		
City	State/Province/Country	ZIP/PostalCode
La Jolla	CALIFORNIA	92037
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Rosebraugh	Curtis	
Street Address 1	Street Address 2	
7946 Ivanhoe Ave, Suite 201	5115617 (dd.1555 2	
City	State/Province/Country	ZIP/PostalCode
La Jolla	CALIFORNIA	92037
Relationship: Executive Officer X Director	_	,2001
Clarification of Response (if Necessary):		
Ciamodion of Nesponse (in Nespossary).		
Last Name	First Name	Middle Name
Humphrey	David	
Street Address 1	Street Address 2	
7946 Ivanhoe Ave, Suite 201		
City	State/Province/Country	ZIP/PostalCode
La Jolla	CALIFORNIA	92037
Relationship: X Executive Officer Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Rauch	Lee	
Street Address 1	Street Address 2	
7946 Ivanhoe Ave, Suite 201		
City	State/Province/Country	ZIP/PostalCode
La Jolla	CALIFORNIA	92037
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
4. Industry Group		

Agriculture	Health Care	Retailing		
Banking & Financial Services	Biotechnology	Restaurants		
Commercial Banking	Health Insurance	Technology		
Insurance	Ц	Computers		
Investing	Hospitals & Physicians			
Investment Banking	Pharmaceuticals	Telecommunications		
Pooled Investment Fund	X Other Health Care	Other Technology		
Is the issuer registered as	Manufacturing	Travel		
an investment company under the Investment Company	Real Estate	Airlines & Airports		
Act of 1940?	Commercial	Lodging & Conventions		
∐Yes ∐No	Construction	Tourism & Travel Services		
Other Banking & Financial Services				
Business Services	REITS & Finance	Uther Travel		
Energy	Residential	Other		
Coal Mining	Other Real Estate			
Electric Utilities	_			
Energy Conservation				
Environmental Services				
Oil & Gas				
Other Energy				
5. Issuer Size				
Revenue Range OR	Aggregate Net	Asset Value Range		
No Revenues	No Aggregate	e Net Asset Value		
\$1 - \$1,000,000	\$1 - \$5,000,0	000		
\$1,000,001 - \$5,000,000	\$5,000,001 -	\$25,000,000		
\$5,000,001 - \$25,000,000	\$25,000,001	- \$50,000,000		
\$25,000,001 - \$100,000,000	\$50,000,001	- \$100,000,000		
Over \$100,000,000	Over \$100,00	00,000		
X Decline to Disclose	cline to Disclose Decline to Disclose			
Not Applicable	Not Applicable			
6. Federal Exemption(s) and Exclusion(s)) Claimed (select all that app	oly)		
	Investme	nt Company Act Section 3(c)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3	(c)(1) Section 3(c)(9)		
Rule 504 (b)(1)(i)	Section 3	(c)(2) Section 3(c)(10)		
Rule 504 (b)(1)(ii)	Section 3	(c)(3) Section 3(c)(11)		
Rule 504 (b)(1)(iii)	Section 3			
X Rule 506(b)				
Rule 506(c)	Section 3	(c)(5) Section 3(c)(13)		
Securities Act Section 4(a)(5)	Section 3	(c)(6) Section 3(c)(14)		
-	Section 3	(c)(7)		
7. Type of Filing				
	14 DFirst Sale Vette Or			
X New Notice Date of First Sale 2024-02-1	14 Pullst Sale Yet to Occur			
Amendment				
8. Duration of Offering				

Does the Issuer intend this offering to last more than one year?	es X No	
9. Type(s) of Securities Offered (select all that apply)		
Equity	Pooled Investment Fund Interests	
Debt	Tenant-in-Common Securities	
X Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities	
Security to be Acquired Upon Exercise of Option, Warrant or Other I Acquire Security	Right to Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combination or exchange offer?	transaction, such as a merger, acquisition	Yes X No
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 USD		
12. Sales Compensation		
Recipient	Recipient CRD Number None	
H.C. Wainwright & Co., LLC	375	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number	X None
None	None	
Street Address 1	Street Address 2	
430 PARK AVENUE City	State/Province/Country	ZIP/Postal Code
NEW YORK	NEW YORK	10022
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
NEW YORK		
40 Official and Color Assessment		
13. Offering and Sales Amounts		
Total Offering Amount \$4,718,295 USD or Indefinite		
Total Amount Sold \$4,718,295 USD		
Total Remaining to be Sold \$0 USD or Indefinite		
Clarification of Response (if Necessary):		
(i) warrants to purchase $7,203,504$ shares of common stock issued in return of the placement agent for $252,123$ shares	exercise of outstanding warrants to purchase 3,601,7	752 shares of common stock and (ii) warrants to
14. Investors		
Select if securities in the offering have been or may be sold to person		and enter the number of
☐ such non-accredited investors who already have invested in the off Regardless of whether securities in the offering have been or may lead to the succession of the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities in the offering have been or may lead to the securities and the securities in the securities in the securities and the securities in the securities and the securities are securities.	9	lited investors enter the
total number of investors who already have invested in the offering:		alted investors, enter the
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders fees check the box next to the amount.	expenses, if any. If the amount of an expenditu	ure is not known, provide an estimate and
Sales Commissions \$265,950 USD Estimate		
Finders' Fees \$0 USD Estimate		
Clarification of Response (if Necessary):		
(i) \$200,000 cash fee, (ii) \$20,000 for non-accountable expenses, (iii) \$30,000 of the shares placed) at an exercise price of \$1.6375 per share	for legal expenses, (iv) \$15,950 for clearing fees an	nd (v) warrants to purchase 252,123 shares (7%
16. Use of Proceeds		

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

	i
\$0 USD	Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the
 accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Ensysce Biosciences, Inc.	/s/ Lynn Kirkpatrick	Dr. Lynn Kirkpatrick	President and CEO	2024-02-20

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.